NCT01696877 - A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

December 18, 2018

Conditions

Prostate Cancer Adenocarcinoma in Situ

Interventions

DRUG

degarelix acetate

Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.

DRUG

Cyclophosphamide

Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.

DRUG

GVAX

GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer

Trial Locations (1)

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore